InspireMD EPS NSPR
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$0.64
- Latest quarter, Q2 FY26
- −$0.17
- Fiscal year 2025
- −$0.35
InspireMD's earnings per share was −$0.64 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.17.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.35 | n/a |
| FY2024 | −$0.78 | n/a |
| FY2023 | −$1.08 | n/a |
| FY2022 | n/a | n/a |
| FY2021 | −$2.05 | n/a |
| FY2020 | −$11.82 | n/a |
| FY2019 | −$108.60 | n/a |
| FY2018 | −$1001.55 | n/a |
| FY2017 | −$37162.50 | n/a |
| FY2016 | −$344662.50 | n/a |
| FY2015 | −$1575525.00 | n/a |
| FY2014 | −$4725000.00 | n/a |
| FY2013 | −$8531250.00 | n/a |
| FY2013 | −$6759375.00 | n/a |
| FY2012 | −$6956250.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.17 | n/a | −$0.64 | |
| Q1 FY26 | −$0.16 | −173% | −$0.73 | |
| Q4 FY25 | −$0.14 | n/a | −$0.35 | |
| Q3 FY25 | −$0.17 | n/a | −$0.40 | |
| Q2 FY25 | −$0.26 | n/a | −$0.39 | |
| Q1 FY25 | $0.22 | n/a | −$0.35 | |
| Q4 FY24 | −$0.19 | n/a | −$0.78 | |
| Q3 FY24 | −$0.16 | n/a | −$0.75 | |
| Q2 FY24 | −$0.22 | n/a | −$0.74 | |
| Q1 FY24 | −$0.21 | n/a | −$0.76 | |
| Q4 FY23 | −$0.16 | n/a | −$1.08 | |
| Q3 FY23 | −$0.15 | n/a | −$1.52 |
Against its peers
Companies in Medical - Instruments & Supplies nearest InspireMD's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NSPRInspireMD | −$0.64 | |
| NEPHNephros | $0.16 | +33% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| Peer median | $1.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on InspireMD
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.